Physics:JNJ-61393215
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | JNJ-3215 |
| Routes of administration | Oral |
| Drug class | Orexin receptor antagonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C23H18F4N4O2 |
| Molar mass | 458.417 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
JNJ-61393215 is an orexin antagonist medication which is under development for the treatment of depression and anxiety disorders.[1][2][3][4] It is an orally active compound and acts as a selective antagonist of the orexin OX1 receptor (1-SORA).[2][3][4] Preliminary clinical findings suggest that JNJ-61393215 may have anti-panic effects in humans.[2][3] As of November 2021, JNJ-61393215 is in phase 2 clinical trials for the treatment of major depressive disorder and is in the preclinical stage of development for treatment of panic disorder, while no further development has been reported for treatment of other anxiety disorders.[1] The drug was originated and developed by Janssen Pharmaceuticals.[1]
See also
- List of investigational antidepressants § Orexin receptor antagonists
- List of investigational anxiolytics
References
- ↑ 1.0 1.1 1.2 "JNJ 61393215 - AdisInsight". https://adisinsight.springer.com/drugs/800045658.
- ↑ 2.0 2.1 2.2 "Experimental Drugs for Panic Disorder: An Updated Systematic Review". J Exp Pharmacol 13: 441–459. 2021. doi:10.2147/JEP.S261403. PMID 33889031.
- ↑ 3.0 3.1 3.2 "Hypocretins (orexins): The ultimate translational neuropeptides". J Intern Med 291 (5): 533–556. May 2022. doi:10.1111/joim.13406. PMID 35043499.
- ↑ 4.0 4.1 "Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans". Transl Psychiatry 10 (1): 308. September 2020. doi:10.1038/s41398-020-00937-9. PMID 32895369.
 |  |
